

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	NO. FILING DATE FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.	
09/530,693	07/03/00	ZENNER		}-	24218
- 026389 HM22/0824			924	EXAMINER	
CHRISTENSEN, O CONNOR, JOHNSON, KINDNESS				MOEZIE,F	
1420 FIFTH		·		ART UNIT	PAPER NUMBER
SUITE 2800 SEATTLE WA	98101-2347		·	1653	8
				DATE MAILED:	
					08/24/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. **09/530.693**

Applicant(s)

Zenner

Examiner

F. MOEZIE

Art Unit 1653



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) X Responsive to communication(s) filed on 4/5/00 and 7/3/00 2a) This action is **FINAL**. 2b) This action is non-final. 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) 1-20 is/are pending in the application. 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) ☐ Claim(s) 6) Claim(s) 7) Claim(s) is/are objected to. _____ are subject to restriction and/or election requirement. 8) X Claims 1-20 **Application Papers** 9) The specification is objected to by the Examiner. 10)☐ The drawing(s) filed on is/are objected to by the Examiner. 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved. 12) \square The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 7, 8 and 20, drawn to a composition and a method for treating disturbances or illnesses of an inner ear, using a peptide that functions as a vasopressin receptor antagonist.

Group II, claim(s) claims 9-13, drawn to a method for treating disturbances or illnesses of an inner ear using a non-peptide organic substance such as a benzazepine derivative or an indole derivative that functions as a vasopressin receptor antagonist.

Claims 1-6, 14-19 are drawn to both Group 1 and Group II claims.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The active substance(s) used in the claims do not share a common special technical feature, hence there is a lack of unity of invention due to the different structures. Furthermore, each invention is searched in a different class/subclass and

Application/Control Number: 09/530,693 Page 3

Art Unit: 1653

the mode of operation is different for each invention. Finally, the consideration of patentability is

different in each case.

NOTE: Upon election of Group I or Group II invention, claims 1-6, and 14-19 will, additionally, be examined along with the elected invention to the extent that they are readable on

the election invention.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37

CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to F.T. Moezie whose telephone number is (703) 4508 or Dr. LOW (SPE) at

308-02923.

J.J. Moegue